| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/30/2011 | CA2784845A1 Use of polysaccharides for treating stress and anxiety |
| 06/29/2011 | EP2339490A1 Method for determining medication efficacy |
| 06/29/2011 | EP2339035A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/29/2011 | EP2339020A1 Diagnostic methods based on Pregnancy-associated plasma protein-A (PAAP-A) |
| 06/29/2011 | EP2338899A1 Peptides for activation and inhibition of delta PKC |
| 06/29/2011 | EP2338886A2 Naphthalene derivatives |
| 06/29/2011 | EP2338524A1 Combined gene therapy for the treatment of macroscopic gliomas |
| 06/29/2011 | EP2338522A1 Antitumoural therapies |
| 06/29/2011 | EP2338519A1 Agent for treating myelofibrosis |
| 06/29/2011 | EP2338518A1 Specific therapy using integrin ligands for treating cancer |
| 06/29/2011 | EP2338517A1 Method for treatment or prevention of disease associated with functional disorder of regulatory T cell |
| 06/29/2011 | EP2338515A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/29/2011 | EP2338511A2 Prolongation of survival of an allograft by inhibiting complement activity |
| 06/29/2011 | EP2338493A1 Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use |
| 06/29/2011 | EP2338492A1 Methods and compositions for the treatment of alzheimer |
| 06/29/2011 | EP2338487A1 Combination therapy with PARP inhibitors |
| 06/29/2011 | EP2338483A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using choline |
| 06/29/2011 | EP2338482A2 Methods for treating neuropsychiatric disorders |
| 06/29/2011 | EP2338481A2 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 06/29/2011 | EP2338448A2 Anti-inflammatory and antimicrobial uses for bioactive glass |
| 06/29/2011 | EP2337868A1 Detection of granulosa-cell tumors |
| 06/29/2011 | EP2337583A1 Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| 06/29/2011 | EP1928499B1 Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| 06/29/2011 | EP1737493B1 Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth |
| 06/29/2011 | EP1658097B1 Nucleotide and cellular vaccine composition |
| 06/29/2011 | EP1379225B1 Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
| 06/29/2011 | EP1180546B1 Human cell lines showing stable expression of cytochromes p450 |
| 06/29/2011 | EP1124567B2 Buffered compositions for dialysis |
| 06/29/2011 | EP1114151B1 G protein-coupled receptor antagonists |
| 06/29/2011 | CN1989963B Pharmaceutical compositions |
| 06/29/2011 | CN102112129A Thiazole compounds, and compositions and methods using same |
| 06/29/2011 | CN102107009A Mixed compound medicament of natural medicament components and nitric oxide donors and application thereof |
| 06/29/2011 | CN102107008A DNA damage repair inhibitors for treatment of cancer |
| 06/29/2011 | CN102107007A Sterides anti-progestogen composition and preparation method thereof |
| 06/29/2011 | CN102107006A Coupling medicament for treating diabetes mellitus and medicinal application thereof |
| 06/29/2011 | CN102107005A Anti-parasite compound preparation for pets |
| 06/29/2011 | CN102107001A Application of LXR nuclear receptor agonist in treatment and prevention of autoimmune diseases |
| 06/29/2011 | CN102106901A Liniment for treating skin diseases of dogs and cats, and preparation process thereof |
| 06/29/2011 | CN102106851A Application of brusatol as chemotherapeutic drug synergist |
| 06/29/2011 | CN102106807A Method for preparing solid preparation and solid preparation |
| 06/29/2011 | CN101048180B Solid formulation with improved solubility and stability, and method for producing said formulation |
| 06/28/2011 | US7968707 Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection |
| 06/28/2011 | US7968680 Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby |
| 06/28/2011 | US7968596 Preparation and diabetic use of Gibberellins |
| 06/28/2011 | US7968569 Anticancer agents; angiogenesis inhibitor; side effect reduction |
| 06/28/2011 | US7968529 Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels |
| 06/28/2011 | US7968523 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides |
| 06/28/2011 | US7968284 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 06/28/2011 | US7968123 Complexing agents for compositions containing inclusion complexes |
| 06/28/2011 | US7968122 Anti-viral pharmaceutical compositions |
| 06/28/2011 | US7968119 Administering antagonist and antagonist removal drug |
| 06/28/2011 | US7968101 Recombinant influenza vectors with tandem transcription units |
| 06/28/2011 | US7968099 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 06/28/2011 | CA2635196C Glucocorticoid receptor modulators |
| 06/28/2011 | CA2526562C Carbostyril derivatives and mood stabilizers for treating mood disorders |
| 06/28/2011 | CA2512608C (2-carboxamido)(3-amino) thiophene compounds |
| 06/28/2011 | CA2506603C Nutritional compositions |
| 06/28/2011 | CA2460026C Porous ceramic composite bone grafts |
| 06/28/2011 | CA2414772C Prevention and treatment of alzheimer's disease |
| 06/28/2011 | CA2190293C Method of cancer treatment by p53 protein control |
| 06/23/2011 | WO2011075620A1 Method for treating haematological cancers |
| 06/23/2011 | WO2011074690A1 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
| 06/23/2011 | WO2011074637A1 Transdermally absorbed preparation of anti-dementia drug |
| 06/23/2011 | WO2011074635A1 Transdermally absorbed preparation of anti-dementia drug |
| 06/23/2011 | WO2011074567A1 Transdermal preparation containing basic anti-inflammatory agent |
| 06/23/2011 | WO2011073981A2 Compositions and methods for treating somnolence |
| 06/23/2011 | WO2011073647A1 Therapeutic combinations of theobromine and an antihistamine |
| 06/23/2011 | WO2011073419A1 New steroid inhibitors of pgp for use for inhibiting multidrug resistance |
| 06/23/2011 | WO2011027344A3 Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders |
| 06/23/2011 | US20110151473 Polynucleotides and Polypeptides Encoding Receptors |
| 06/23/2011 | US20110151472 Novel means for the diagnosis and therapy of ctcl |
| 06/23/2011 | US20110151030 Compositions for alleviating inflammation and oxidative stress in a mammal |
| 06/23/2011 | US20110150877 Ephrin-b receptor protein involved in carcinoma |
| 06/23/2011 | CA2784215A1 Therapeutic combinations of theobromine and an antihistamine |
| 06/22/2011 | EP2336368A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/22/2011 | EP2336359A1 1L1RL-1 as a cardiovascular disease marker and therapeutic target |
| 06/22/2011 | EP2336321A1 Ox2 receptor homolog |
| 06/22/2011 | EP2336184A2 Administration of agents for the treatment of inflammation |
| 06/22/2011 | EP2336168A1 Novel protein and method for producing the protein |
| 06/22/2011 | EP2336167A1 MHC molecule constructs and their uses for diagnosis and therapy |
| 06/22/2011 | EP2336166A1 Compositions that inhibit proliferation of cancer cells |
| 06/22/2011 | EP2335734A2 Treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 06/22/2011 | EP2335733A1 Specific therapy using integrin ligands for treating cancer |
| 06/22/2011 | EP2335728A1 Specific binding proteins and uses thereof |
| 06/22/2011 | EP2335709A1 Insulin resistance improving agent |
| 06/22/2011 | EP2335704A1 Pharmaceutical composition comprising a strontium salt, vitamine D and a cyclodextrine |
| 06/22/2011 | EP2335702A1 Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent |
| 06/22/2011 | EP2335700A1 Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| 06/22/2011 | EP2335699A1 Synergistic combination of analgesic compounds |
| 06/22/2011 | EP2335694A1 Thyroid hormone analogs and methods of use. |
| 06/22/2011 | EP2334306A2 Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| 06/22/2011 | EP2334299A1 Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat |
| 06/22/2011 | EP2334295A1 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| 06/22/2011 | EP2334293A2 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses |
| 06/22/2011 | EP2334292A1 Method of determining a phosphorus binder dosage for a dialysis patient |
| 06/22/2011 | EP2334185A1 Compositions and methods of using (r)-pramipexole |
| 06/22/2011 | EP2334182A1 Method of treating organophosphorous poisoning |
| 06/22/2011 | EP2334180A1 Alleviating disorders with combining agents that increase epoxygenated fatty acids and agents that increase camp |
| 06/22/2011 | EP2334176A1 Topical formulations for treatment of neuropathy |
| 06/22/2011 | EP1888624B1 Method of purifying apo-2 ligand/trail using crystallisation in the cold |